Literature DB >> 25351191

Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.

Laura Scaramucci1, Marco Giovannini1, Pasquale Niscola1, Andrea Tendas1, Alessio Perrotti1, Paolo De Fabritiis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25351191      PMCID： PMC4212042          DOI： 10.2450/2014.0246.13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  9 in total

1.  Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.

Authors:  Andrea Piccin; Giovanni Amaddii; Fabrizio Natolino; Atto Billio; Sergio Cortelazzo
Journal:  Blood Transfus       Date:  2013-04-17       Impact factor: 3.443

2.  Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.

Authors:  Shokichi Tsukamoto; Chiaki Nakaseko; Masahiro Takeuchi; Kyoya Kumagai; Tsunehiko Komatsu; Hiroaki Tanaka; Satoru Hara; Masayuki Koizumi; Hidenori Imai; Akira Yokota; Masami Takeuchi; Koiti Inokuchi; Yasuhiro Matsuura; Nobuyuki Aotsuka; Hisashi Wakita
Journal:  Br J Haematol       Date:  2013-07-17       Impact factor: 6.998

Review 3.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

Review 4.  Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.

Authors:  Katy L Cooper; Patrick Fitzgerald; Kerry Dillingham; Kawitha Helme; Ron Akehurst
Journal:  Int J Technol Assess Health Care       Date:  2012-07       Impact factor: 2.188

5.  Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.

Authors:  V Noronha; S D Philip; A Joshi; K Prabhash
Journal:  Int J Hematol       Date:  2012-08-01       Impact factor: 2.490

6.  No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.

Authors:  Giovanni D'Arena; Roberto Guariglia; Giovanna Mansueto; Maria Carmen Martorelli; Giuseppe Pietrantuono; Oreste Villani; Rosa Lerose; Pellegrino Musto
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

7.  Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.

Authors:  Nicola Polverelli; Francesca Palandri; Ilaria Iacobucci; Lucia Catani; Giovanni Martinelli; Nicola Vianelli
Journal:  Br J Haematol       Date:  2012-12-29       Impact factor: 6.998

Review 8.  International consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter
Journal:  Blood       Date:  2009-10-21       Impact factor: 22.113

9.  Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Authors:  T Aoki; Y Harada; E Matsubara; T Suzuki; T Oyama; M Kasai; T Uchida; M Ogura
Journal:  J Clin Pharm Ther       Date:  2012-05-14       Impact factor: 2.512
  9 in total
  4 in total

1.  Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.

Authors:  Fabian Depré; Nasra Aboud; Beate Mayer; Abdulgabar Salama
Journal:  Blood Transfus       Date:  2017-01-25       Impact factor: 3.443

2.  Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.

Authors:  Yeo-Kyeoung Kim; Seung-Sin Lee; Sung-Hoon Jeong; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2015-03-24

3.  Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?

Authors:  Massimiliano Palombi; Laura Scaramucci; Marco Giovannini; Malgorzata Monika Trawinska; Pasquale Niscola; Paolo de Fabritiis
Journal:  Blood Res       Date:  2016-03-25

4.  Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821).

Authors:  Vidya P Kumar; Gregory P Holmes-Hampton; Shukla Biswas; Sasha Stone; Neel Kamal Sharma; Bernadette Hritzo; Mary Guilfoyle; Gary Eichenbaum; Chandan Guha; Sanchita P Ghosh
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.